Search clinical trials for: Raltegravir Truvada

Total 470 results

Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC

Completed

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients (RAN)

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

HIV
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Merck Sharp & Dohme LLC

Completed

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

HIV Infections

France
Fenway Community Health
Merck Sharp & Dohme LLC

Completed

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

HIV Infections

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

HIV Infection | Hepatitis C

United States
Margaret A. Fischl, M.D.

Completed

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects (HIV)

HIV Infections

United States
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
Community Research Initiative of New England
Merck Sharp & Dohme LLC

Withdrawn

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

HIV Infections | Acquired Immune Deficiency Syndrome
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
Kirby Institute

Completed

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

HIV Infections
Community Research Initiative of New England
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

HIV

United States
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Completed

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. (ROaR+)

Cardiovascular Disease | HIV

Australia
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
University of North Carolina, Chapel Hill

Completed

A Key Link for Transmission Prevention (MP3)

HIV

Malawi
ViiV Healthcare

Completed

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
Projeto Praça Onze
Merck Sharp & Dohme LLC

Unknown

A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection (PERIEP)

HIV | Infection

Brazil
Pedro Cahn
Merck Sharp & Dohme LLC

Unknown

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients (ARTE)

Chronic Infection With HIV

Argentina
Dallas VA Medical Center
Merck Sharp & Dohme LLC; Tibotec Pharmaceutical Limited

Completed

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
Abbott
Merck Sharp & Dohme LLC

Completed

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) (PROGRESS)

Human Immunodeficiency Virus Infection

United States, Canada, France, Italy, Poland, Puerto Rico, Spain
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
Bristol-Myers Squibb

Completed

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients (SPARTAN)

HIV, Combination Therapy

France, Germany, Spain, United States, Italy, Poland, United Kingdom
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Terminated

Phase IIB Pilot of Atazanavir + Raltegravir (SPARTAN)

HIV

Argentina, United States, France
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
St Stephens Aids Trust

Completed

Raltegravir and Ezetimibe PK Study

HIV

United Kingdom
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
George Washington University

Terminated

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

HIV Infections

United States
Universidad Peruana Cayetano Heredia
Merck Sharp & Dohme LLC

Completed

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

HTLV-I Infections | Tropical Spastic Paraparesis

Peru
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

HIV Infections | Tuberculosis

South Africa
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

HIV Infections

Austria
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. (AVIATOR)

HIV | Hypercholesterolaemia

Netherlands
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Hiv | Prophylaxis | Transgender

United States
National Institute of Neurological Disorders and...

Completed

Raltegravir for HAM/TSP

HTLV-I Infection

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Human T-cell Leukemia Virus Type 1 Infection
Community Research Initiative of New England

Completed

BRAVO: Background Regimen of Raltegravir on Virologic Outcome (BRAVO)

HIV Infections

United States
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

HIV Infections | HIV-1

Spain
University of Rochester
Merck Sharp & Dohme LLC

Completed

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women

HIV Infections

United States
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study (NEARQD)

HIV Infections

Spain
Queen Mary University of London
Merck Sharp & Dohme LLC

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis

United Kingdom
The Miriam Hospital
Merck Sharp & Dohme LLC; Tufts Medical Center

Completed

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

HIV Infections | HIV | Hypertriglyceridemia | Hyperlipidemia

United States

Search clinical trials for: Raltegravir Truvada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations